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Aims We tested whether delayed pharmacologic preconditioning elicited by isoﬂurane is protective in
infarct-remodelled hearts.
Methods and results Male Wistar rats were treated with the preconditioning drug isoﬂurane 6 weeks
after permanent ligation of the left anterior descending coronary artery. Twenty-four and 48 h later,
hearts were perfused on the Langendorff system and treated with cyclooxygenase-2 or 12-lipoxygenase
inhibitors before exposure to 40 min of ischaemia followed by 90 min of reperfusion. Infarct size was
determined by triphenyltetrazolium chloride staining and lactate dehydrogenase release. Cyclooxygen-
ase-2 expression and activity were measured by Western blotting and colorimetric assay. Nuclear
translocation of cyclooxygenase-2-inducing transcription factors HIF1a, CREB, STAT3, and NFkB was
determined. Post-infarct, remodelled hearts exhibit alterations in cellular signalling, time course and
extent of isoﬂurane-induced late protection. While remodelled, preconditioned hearts exhibited pro-
tection exclusively at 24 h, healthy hearts showed sustained protection for up to 48 h, which correlated
with cyclooxygenase-2 protein expression and enzymatic activity. The cyclooxygenase-2 inhibitors
celecoxib and NS-398, but not the 12-lipoxygenase inhibitor cinnamyl-3,4-dihydroxycyanocinnamate,
abolished delayed protection in both healthy and remodelled hearts, identifying cyclooxygenase-2 as
a key mediator of late protection in both models. Isoﬂurane induced nuclear translocation of HIF1a
in all hearts, but CREB was exclusively activated in healthy but not remodelled myocardium, which
expressed higher levels of the CREB antagonist ICER. Delayed protection by isoﬂurane in remodelled
hearts was more vulnerable to inhibition by celecoxib.
Conclusion Isoﬂurane failed to mobilize cyclooxygenase-2-inducing CREB in ICER-overexpressing,
remodelled hearts, which was associated with a shortening of the second window of protection.
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1. Introduction
In 1993, Marber et al.1 and Kuzuya et al.2 described a
remarkable phenomenon called delayed ischaemic precon-
ditioning of the heart, which reﬂects a late ‘window of pro-
tection’ against ischaemia, usually occurring 12–72 h after
brief repetitive ischaemic episodes. The resulting protective
phenotype of the heart is due to a profound transcriptional
reprogramming with de novo protein synthesis, and is of
great clinical relevance, as it is 30-times longer than the
early window, which only lasts 2–3 h.3 Today, we know
that early and delayed preconditioning of the heart can be
elicited more safely by pharmacologic means such as haloge-
nated ethers or opioids than by ischaemic episodes.4,5 This is
of particular relevance for the already jeopardized diseased
myocardium. Isoﬂurane-induced delayed protection was ﬁrst
reported in 2003 in a rabbit model by Toncovic-Capin et al.6
In healthy rabbit myocardium, celecoxib, a speciﬁc
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cyclooxygenase-2 (COX-2) inhibitor, abolished delayed
isoﬂurane preconditioning,7 while late isoﬂurane protection
was dependent on 12-lipoxygenase activity in healthy
murine hearts.8 Recently, molecular evidence of delayed
anaesthetic preconditioning after sevoﬂurane inhalation
has been also reported in humans.9
Most experimental studies evaluated the phenomenon of
early and delayed preconditioning in healthy juvenile
hearts, but this is far from clinical reality, as diseasedmyocar-
dium would beneﬁt most from this protection. Some studies
reported reduced protection in the early phase of precondi-
tioning in diseased hearts.10,11 Since the early phase of pre-
conditioning is based on similar signalling pathways as the
late phase, it could be speculated that protection during
the late phase would be impaired in remodelled hearts. Post-
infarct remodelled myocardium exhibits marked structural
changes,12 alterations in energy metabolism13 and cellular
signalling,14 which put the heart at particular risk for
further ischaemic damage. In contrast to this notion are our
own recent ﬁndings that post-infarct remodelled hearts
remain receptive to protection by early isoﬂurane precondi-
tioning via the same signalling pathways, as observed in
healthy hearts.15 Nonetheless, no data exist as to whether
delayed anaesthetic protection retains its effectiveness in
post-infarct myocardium. Using an established rat model of
ventricular remodelling after permanent coronary artery lig-
ation, we investigated whether ventricular remodelling
would affect late isoﬂurane protection. Speciﬁcally, we
hypothesized that remodelling would abolish late isoﬂurane
protection and increase the vulnerability of the heart to
ischaemia-reperfusion injury. This study also investigated
possiblemechanisms underlying thepostulated refractoriness
to late anaesthetic protection in remodelled hearts.
The current study shows that the isoﬂurane-induced
second window of protection shrinks to a short-lived phase
in remodelled myocardium, which would require repetition
of the preconditioning stimulus every 24 h to maintain the
heart in the protected state.
2. Methods
This animal study was performed according to the guidelines
of the Animal Care and Use Committee of the University of
Zurich, Switzerland. All experimental procedures conformed
to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH publi-
cation 85-23, revised 1996).
2.1 Post-infarct remodelled hearts
Myocardial infarction (35% of left ventricular mass) and
subsequent hypertrophic remodelling was induced in male
adult (180–200 g, 8–9 weeks old) Wistar rats by permanent
ligation of the left anterior descending coronary artery
(LAD) under anaesthesia, as previously described in
detail.16 Some animals served as control and underwent
the same procedure except that the suture was passed
under the coronary artery without ligation. Rats were sacri-
ﬁced 6 weeks after surgery, and the body weight and heart
weight were measured. Hearts were further evaluated for
their function on a Langendorff apparatus (see Supplemen-
tary material online, Table S1).
2.2 Protocol for delayed isoﬂurane preconditioning
Healthy age-matched rats and infarct rats 6 weeks after cor-
onary artery ligation were placed on a thermoregulating pad
and exposed to 2.1 vol% [1.5 minimum alveolar concen-
tration (MAC) in rats] isoﬂurane (Abbott, Bar, Switzerland)
in oxygen for 90 min by inhalation (Figure 1). Rats exposed
to 100% oxygen for 90 min served as sham control. The con-
centration of applied isoﬂurane was continuously monitored
using a gas monitor. In separate experiments, a catheter was
inserted in the femoral artery and arterial blood was with-
drawn for blood gas analysis (see Supplementary material
online, Table S2). The animals subsequently recovered in
room air (21 vol% oxygen). Twenty-four and 48 h later,
delayed protection against ischaemia-reperfusion injury
was assessed on a Langendorff apparatus (Figure 1).
2.3 Isolated perfused rat heart experiments
Rats were heparinized (500 units i.p.) and 15 min later
decapitated without prior anaesthesia. Hearts were
mounted on a non-circulating Langendorff apparatus and
perfused with Krebs–Henseleit buffer gassed with 95% O2
and 5% CO2 at pH 7.4 and 378C, as previously described.
17
Five hearts were assigned to each experimental group
(Figure 1). The selective COX-2 inhibitors celecoxib (CEL,
Pﬁzer AG, Zurich, Switzerland, IC50 ¼ 0.04 mM, low dose
used 0.1 mM, high dose used 1 mM), N-2-cyclohexyloxy-
4-nitrophenyl-methanesulphonamide (NS-398, Cayman
Chemical, Ann Arbor, MI, IC50 ¼ 1.77 mM, used concentration
5 mM) and the selective 12-lipoxygenase inhibitor
cinnamyl-3,4-dihydroxycyanocinnamate (CDC, USBiological,
Swampscott, MA, IC50 ¼ 0.063 mM, used concentration
0.5 mM) were dissolved in 0.1% dimethyl sulphoxide (DMSO)
vehicle and used to perfuse the hearts for 10 min before
induction of global ischaemia (Figure 1). Infarct size was
determined by 1% 2,3,5-triphenyltetrazolium chloride stain-
ing after 90 min of reperfusion, as previously described.16,18
In addition, myocardial damage was estimated by measuring
the release of lactate dehydrogenase (LDH) from necrotic
tissue, as previously described.16 Brieﬂy, the perfusate was
collected and LDH activity was determined by the Roche/
Hitachi 917 kit (sensitivity 6 U/L, intra- and interassay coef-
ﬁcients of variance ,1%).
2.4 Western blot analysis
Separate experiments served to determine expression of
12-lipoxygenase, 5-lipoxygenase, and COX-2 in healthy and
remodelled hearts 24 and 48 h after isoﬂurane exposure by
Western blot analysis. The antibodies were from the follow-
ing sources: COX-2, Cell Signaling Technology, Beverly, CA,
USA; 12-lipoxygenase, Cayman Chemical; 5-lipoxygenase,
BD Biosciences, San Diego, CA, USA; a-tubulin, Sigma, St
Louis, MO, USA.
2.5 COX-2 activity assay
Left ventricular tissue was homogenized in cold homogeniz-
ation buffer (0.1 M Tris-HCl, pH 7.8 containing 1 mM EDTA).
After centrifugation at 10 000 g for 20 min, the supernatant
was collected for enzyme assay. COX-2 activity was
measured in the presence of a potent and selective
cyclooxygenase-1 inhibitor SC-560 (Cayman Chemical, IC50
for cyclooxygenase-1 ¼ 9 nM and for cyclooxygenase-2 ¼
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6.3 mM) using a chromogenic cyclooxygenase activity assay
kit according to the manufacturer’s instruction (Cayman
Chemical). This assay measures the colour reaction of
cyclooxygenase-generated hydroperoxides.19
2.6 Electrophoretic mobility shift assays
Nuclear proteins were extracted as previously described in
detail.20 Electrophoretic mobility shift assays (EMSAs) were
performed with Odysseyw IRDyew 700 infrared dye labelled
double-stranded oligonucleotides coupled with the EMSA
buffer kit (LI-COR Bioscience, Bad Homburg, Germany)
according to the manufacturer’s instructions. Brieﬂy, 10–
20 mg of nuclear extract was incubated with 1–1.5 mL of
IRDyew 700 infrared dye labelled oligonucleotides, 2 mL of
10 binding buffer, 2.5 mM DTT, 0.25% Tween, and 1 mg of
poly (dI-dC) in a total volume of 20 mL for 30 min at room
temperature. For CREB binding assay a ﬁnal concentration
of 0.05% NP-40 was added, and for STAT3 binding assay a
ﬁnal concentration of 0.05% NP-40 and 5 mM MgCl were
added. Samples were separated on a 4% polyacrylamide
gel in 0.5 tris-borate-EDTA running buffer for 2 h at 200
V. The gel was then scanned by direct infrared ﬂuorescence
detection on the Odysseyw Imaging System (LI-COR Bio-
science). Oligonucleotide sequences of the double-stranded
DNA probes used were as follows: HIF-1a, 50-AGC TTG CCC
TAC GTG CTG TCT CAG A-30; CREB, 50-AGA GAT TGC CTG
ACG TCA GAG AGC TAG-30; NFkB, 50-AGT TGA GGG GAC
TTT CCC AGG C-30; STAT3, 50-GAT CCT TCT GGG AAT TCC
TAG ATC-30. The speciﬁcity of the DNA-protein binding
signal was conﬁrmed by competition with 200-fold molar
excess of the unlabelled consensus competitor
oligonucleotide.
2.7 Real-time quantitative polymerase chain
reaction
Details are provided in the Supplementary Materials and
Methods.
2.8 Statistical analysis
Data are presented as mean+ SD. For cardiac functional
data, repeated-measures analysis of variance was used to
evaluate differences over time between groups. Unpaired
t-test was used to compare groups at identical time
points, and paired t-test to compare within groups over
time. P-values were multiplied by the number of compari-
sons (Bonferroni correction). Post-hoc Tukey test was
applied for multiple comparisons of the one-way analysis
of variance for all other data. P, 0.05 was considered as
signiﬁcant. SigmaStat (version 2.0; SPSS Science, Chicago,
IL, USA) was used for the analyses.
3. Results
3.1 Post-infarct remodelling narrows the second
window of protection after isoﬂurane
preconditioning
From the 106 rats used for coronary artery ligation, 10
animals were lost intraoperatively due to intractable ventri-
cular ﬁbrillation. Heart weight over body weight ratios
determined 6 weeks after surgery were markedly higher in
post-infarct hearts compared with age-matched healthy or
sham-operated hearts (remodelled: 5.52+0.70 g/kg,
healthy: 3.58+0.57 g/kg, sham-operated: 3.63+0.55 g/
kg, P , 0.05; see Supplementary material online, Table
S1), indicating signiﬁcant ventricular remodelling. In
addition, left ventricular developed pressure, coronary
ﬂow, and heart rate were determined ex vivo on the Langen-
dorff apparatus. Left ventricular developed pressure was
lower in remodelled hearts compared with age-matched
healthy hearts. No changes were observed between groups
for coronary ﬂow and heart rate (see Supplementary
material online, Table S1).
Preconditioning elicited by isoﬂurane inhalation at 1.5
MAC for 90 min signiﬁcantly improved functional recovery
(see Supplementary material online, Table S3 and S4) and
decreased infarct size after ischaemia-reperfusion in both
healthy and remodelled hearts (Figures 2A and 3A).
However, protection in infarct hearts was exclusively
present at 24 h after preconditioning, while in healthy
hearts the protection extended from 24 to 48 h after isoﬂur-
ane exposure. Infarct-size reduction was corroborated with
measurements of LDH release into the perfusate during
reperfusion in healthy and remodelled hearts (Figures 2B
Figure 1 Treatment protocols. Six weeks after ligation of the left anterior descending coronary artery (LAD), rats were exposed in vivo to 2.1 vol% (1.5 MAC)
isoﬂurane in oxygen or oxygen alone for 90 min. Age-matched healthy rats served as control group. Twenty-four and 48 h after isoﬂurane preconditioning, Lan-
gendorff perfused healthy and remodelled hearts were exposed to 40 min of ischaemia and 90 min of reperfusion. Blockers were administered 10 min before
index ischaemia. MAC: minimum alveolar concentration.
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and 3B). Sham groups (oxygen inhalation alone) did not
exhibit protection 24 or 48 h later in either model. The
recovery of developed pressure after delayed precondition-
ing was lower by 20% in remodelled hearts when compared
with healthy hearts, and end-diastolic pressure reached
baseline values after 90 min of reperfusion in healthy but
not remodelled hearts (see Supplementary material online,
Tables S3 and S4). Groups with celecoxib administration
before ischaemia-reperfusion exhibited increased coronary
ﬂow consistent with previous reports.21 Of note, during trig-
gering of isoﬂurane preconditioning, arterial blood gas
measurements did not show signiﬁcant differences com-
pared with animals treated with oxygen alone (see Sup-
plementary material online, Table S2). These results
provide evidence that post-infarct remodelling narrows
the second window of protection after isoﬂurane
preconditioning.
3.2 Late protection by isoﬂurane preconditioning is
more vulnerable to cyclooxygenase-2 inhibition in
remodelled myocardium
COX-2 and 12-lipoxygenase were shown to be important in
mediating delayed cardioprotection by isoﬂurane.7,8 Here
we show that delayed protection by isoﬂurane is abolished
or attenuated by inhibitors of COX-2, but not of
12-lipoxygenase (Figures 2 and 3). While delayed protection
was more resistant to celecoxib in healthy hearts, remo-
delled hearts completely lost protection in the presence of
even lower celecoxib concentrations (see Supplementary
material online, Tables S3 and S4). Dimethyl sulphoxide
alone or blockers alone had no effect on infarct size.
Taken together, the data provide evidence that delayed pro-
tection by isoﬂurane is mediated by COX-2 in both healthy
and remodelled hearts and further underscore the
Figure 2 Infarct size (A) and lactate dehydrogenase (LDH) release (B) in healthy hearts. ISO24/48: hearts exposed to ischaemia-reperfusion 24 or 48 h after
isoﬂurane preconditioning. ISO24/48_CEL_high: preconditioned hearts treated with 1 mM celecoxib. ISO24/48_CEL_low: preconditioned hearts treated with
0.1 mM celecoxib. ISO24/48_CDC: preconditioned hearts treated with 0.5 mM cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC). ISO24/48_NS398: preconditioned
hearts treated with 5 mM N-2-cyclohexyloxy-4-nitrophenyl-methane-sulphonamide (NS-398). Final concentration of dimethyl sulphoxide (DMSO) was ,0.1%.
The preﬁx SHAM in group names indicates respective groups without isoﬂurane preconditioning (oxygen alone). *P , 0.05 vs. SHAM24 groups. #P , 0.05 vs.
SHAM48 groups. **P , 0.05 vs. high celecoxib concentration. Data are mean+ SD (n ¼ 5 per group).
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remarkable vulnerability of the diseased myocardium to
COX-2 inhibition.
3.3 Isoﬂurane-induced cyclooxygenase-2
expression and activity show alterations in
remodelled hearts
As expected, COX-2 was more abundant in infarct hearts
(see Supplementary material online, Figure S1).22 To charac-
terize the expression and activity of COX-2 in delayed
protection by isoﬂurane preconditioning, Western blot
analyses (Figure 4) and activity measurements (Figure 5)
were performed in isoﬂurane- and sham-treated rat hearts
24 and 48 h after triggering with isoﬂurane. In healthy
hearts, COX-2 expression was increased 24 (1.5-fold) and
48 h (2.7-fold) after isoﬂurane exposure, while in remo-
delled hearts, COX-2 expression was exclusively increased
at 24 h (three-fold) (Figure 4). Oxygen inhalation in sham
groups did not affect COX-2 expression or activity. COX-2
activity closely paralleled COX-2 expression (Figure 5). No
changes in 12-lipoxygenase and 5-lipoxygenase expression
were observed (see Supplementary material online, Figure
S2). Together, isoﬂurane-induced COX-2 showed a shortened
activation proﬁle in remodelled hearts, which closely paral-
leled structural and functional protection.
3.4 Isoﬂurane induces nuclear translocation of
HIF1a but not CREB in post-infarct remodelled
hearts
To determine the contribution of putative transcription
factors in the observed isoﬂurane-induced COX-2 expression
in healthy and remodelled hearts, nuclear translocation of
NFkB, STAT3, HIF1a, and CREB was measured 30 min after
termination of isoﬂurane inhalation (2.1 vol% for 90 min) in
additional experiments. Isoﬂurane induced nuclear
translocation of HIF1a in healthy and remodelled hearts
(Figure 6). In contrast, CREB was exclusively translocated
to nuclei in healthy hearts. None of the other transcription
factors was activated by isoﬂurane compared with sham
Figure 3 Infarct size (A) and lactate dehydrogenase (LDH) release (B) in remodelled hearts. ISO24/48: hearts exposed to ischaemia-reperfusion 24 or 48 h after
isoﬂurane preconditioning. ISO24/48_CEL_high: preconditioned hearts treated with 1 mM celecoxib. ISO24/48_CEL_low: preconditioned hearts treated with
0.1 mM celecoxib. ISO24/48_CDC: preconditioned hearts treated with 0.5 mM cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC). ISO24/48_NS398: preconditioned
hearts treated with 5 mM N-2-cyclohexyloxy-4-nitrophenyl-methane-sulphonamide (NS-398). Final concentration of dimethyl sulphoxide (DMSO) was ,0.1%.
The preﬁx SHAM in group names indicates corresponding groups without isoﬂurane preconditioning (oxygen alone). *P, 0.05 vs. SHAM24 group. Data are
mean+ SD (n ¼ 5 per group).
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treatment (data not shown). In search of possible mechan-
isms for the lack of CREB activation by isoﬂurane in remo-
delled myocardium, we determined the mRNA level of the
CREB-antagonist inducible cAMP early repressor (ICER),
which was increased by 63% in remodelled myocardium:
0.026+;0.005 vs. 0.016+;0.004 (arbitrary units relative
to a-tubulin, P ¼ 0.009). These data suggest that the
failure of isoﬂurane to activate CREB in remodelled
myocardium may be due to overexpression of the
CREB-antagonist ICER in infarct hearts and thus may contrib-
ute to the observed narrowing of the second window of
protection.
Figure 4 Representative Western blots of cyclooxygenase-2 (COX-2) expression (72 kDa) in healthy (A) and remodelled (B) hearts 24 and 48 h after isoﬂurane
exposure expressed as average density ratio of COX-2 to a-tubulin (57 kDa) normalized to baseline (BL). ISO24/48: hearts exposed to isoﬂurane and harvested 24
or 48 h later. SHAM24/48: time-matched hearts exposed to oxygen alone. Data are mean+ SD (n ¼ 4 per group). *P , 0.05 vs. BL.
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4. Discussion
The salient ﬁndings of this study can be summarized as
follows. First, isoﬂurane induced a robust but narrow
second window of protection in hearts with marked
post-infarct ventricular remodelling. In these diseased
hearts, reduction in infarct size and improved functional
recovery were only present 24 h after isoﬂurane application,
while in healthy hearts protection extended for up to 48 h.
Secondly, delayed protection by isoﬂurane in rat hearts
was mediated by COX-2 but not 12-lipoxygenase in both
remodelled and healthy myocardium, and closely correlated
with increased COX-2 expression and activity levels. Hence,
isoﬂurane elicits late protection in remodelled rat myocar-
dium via similar signalling pathways as previously reported
in healthy rabbit hearts.7 While COX-2-inducing HIF-1a was
activated by isoﬂurane in healthy and remodelled hearts,
isoﬂurane failed to mobilize COX-2-inducing CREB in post-
infarct myocardium. Overexpression of the CREB-antagonist
ICER offers an explanation for the observed narrowing of the
second window of protection, a hypothesis that needs vali-
dation. Thirdly, despite increased expression of COX-2,
remodelled preconditioned hearts exhibited a remarkable
vulnerability to inhibition by the clinically used anti-
inﬂammatory drug celecoxib, which completely abolished
delayed isoﬂurane protection in these hearts, but only
partly diminished the protection in healthy hearts. Together,
we present for the ﬁrst time evidence that delayed protec-
tion by isoﬂurane preconditioning varies with the disease
state of the heart and concomitant medication (Figure 7).
Since recruitment of COX-2 is a critical innate mechanism,
whereby the heart protects itself from ischaemia,3 our ﬁnd-
ings may be of relevance for the medical management of
patients at risk of cardiovascular complications.
Delayed preconditioning is a second window of protec-
tion whereby stimulation by ischaemia or chemical agents
enhances the resistance of the heart to subsequent poten-
tially lethal stimuli 24–72 h later. It is a universal response
Figure 5 Cyclooxygenase-2 (COX-2) activity in healthy (A) and remodelled
(B) hearts 24 and 48 h after isoﬂurane exposure. ISO24/48: hearts exposed
to isoﬂurane and harvested 24 or 48 h later. SHAM24/48: time-matched
hearts exposed to oxygen alone. Data are mean+ SD (n ¼ 4 per group).
*P , 0.05 vs. baseline (BL).
Figure 6 Electrophoretic mobility shift assays of HIF1a and CREB in healthy (A) and remodelled (B) hearts (gels with corresponding densitometry). ISO30 min:
nuclear extracts from hearts exposed to isoﬂurane preconditioning harvested 30 min after termination of inhalation (2.1 vol% for 90 min). SHAM30 min: nuclear
extracts from respective sham group (oxygen alone). Gels show additional lines with ISO30 min plus 200-fold excess of unlabelled consensus competitor oligo-
nucleotide (comp. oligo) conﬁrming speciﬁcity of the detected ﬂuorescence signal for HIF1a and CREB, respectively. Data are mean + SD (n ¼ 4 per group).
*P , 0.05 vs. baseline (BL) and healthy hearts, respectively. †P, 0.05 vs. ISO30 min.
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of the heart to stress.23 In contrast to early precondition-
ing, delayed preconditioning has strong and more reliable
anti-stunning and anti-infarct effects making it more clini-
cally relevant. It causes an increase in prostaglandin bio-
synthesis in cardiac tissue via the enhanced expression of
COX-2 catalysing the conversion of arachidonic acid to
prostanoids.24 COX-2 is constitutively expressed in the
heart at lower levels25 but rapidly induced through the
activation of several transcription factors.3,23 Prostanoids
such as prostacyclin (PGI2) open mitochondrial KATP chan-
nels,26 key players in isoﬂurane-induced cardioprotec-
tion.27 Inhibition of the rate-limiting enzyme COX-2
abolishes the infarct-sparing effect of delayed precondi-
tioning,24 but also the protection by early precondition-
ing.28 Using healthy animal models from different
species, previous studies reported on late cardioprotection
after exposure to volatile anaesthetics,29,30 and identiﬁed
reactive oxygen and nitrogen species released by nitric
oxide synthase as triggers,31 inducible nitric oxide
synthase,32 12-lipoxygenase,8 and endothelial nitric oxide
synthase33 as mediators, and sarcolemmal and mitochon-
drial KATP channels as end effectors
6 of delayed anaesthetic
preconditioning. Hitherto, however, only one study with
healthy rabbit hearts investigated the role of COX-2 in
isoﬂurane-induced delayed preconditioning using the
COX-2 inhibitor celecoxib.7 Our study now conﬁrms COX-2
as an obligatory mediator in isoﬂurane-induced delayed
preconditioning of healthy rat hearts, and further extends
its critical role in cardioprotection to diseased post-infarct
remodelled myocardium.
Structural changes due to loss of viable tissue and scar for-
mation,12 alterations in metabolism,13 and cellular signal-
ling14,34,35 put the remodelled myocardium at risk for
further ischaemic damage. Experiments from muscle slices
of right atrial appendices of patients with failing hearts indi-
cate that remodelled myocardium is less amenable to innate
protection by preconditioning.36 At the molecular level, a
gene program resembling the foetal program is activated
and protective signalling pathways were reported to be
lost in various disease models associated with remodelling.37
Complete refractoriness to early ischaemic preconditioning
as opposed to pharmacologic preconditioning by diazoxide,
was reported in a rabbit infarct model, for which interrup-
tion of signal transduction between G-protein coupled
receptors and protein kinase C was found to be respon-
sible.38 Conversely, erythropoietin-mediated precondition-
ing was preserved in post-infarct remodelled rat
myocardium despite the disruption of the erythropoietin
receptor–PI3K–PKB pathway via up-regulation of the sup-
pressor of cytokine signalling protein-1.39 In this case, com-
pensatory PI3K-independent activation of ERK upstream of
the guanylyl cyclase-mitochondrial KATP channel pathway
restored the protective phenotype. To date, no data is avail-
able with respect to delayed protection after pharmacologic
or ischaemic preconditioning in post-infarct remodelled
hearts. In contrast to our previous ﬁndings on early
isoﬂurane-induced preconditioning15 and postconditioning
in remodelled myocardium,16 where protection against
ischaemia-reperfusion was fully preserved, our current
study on delayed isoﬂurane preconditioning clearly indicates
that ventricular remodelling alters protective signalling ren-
dering the heart more vulnerable to ischaemia-reperfusion
injury. In search of mechanisms for this remarkable vulner-
ability, we tested a number of COX-2-inducing transcription
factors to see whether their nuclear translocation would be
impaired in the diseased state. Increased HIF1a protein
levels were previously reported after isoﬂurane exposure
in rat myocardium40 and were similarly regulated in the
current study in healthy and diseased hearts. HIF1a is an
oxygen-dependent transcription factor activating an array
of genes required for the adaptation to hypoxia, including
COX-2. In contrast, CREB was exclusively mobilized in
healthy but not remodelled hearts, which showed increased
expression of the transcriptional repressor and
CREB-antagonist ICER.41 ICER represses transcription either
by heterodimerization with activating forms of CREB and
other bZIP domain-containing transcription factors, or by
competing with these proteins for DNA binding.42 Due to
the homology between ICER and CREB, we cannot comple-
tely rule out that both CREB and ICER bind to the CRE-
consensus oligos used in our experiments. However, the
DNA-binding activity is lower in remodelled hearts than in
healthy hearts indicating that ICER may not or only weakly
bind to CREB-oligos (data not shown). The results of our
experiments raise the possibility that the observed lack of
CREB-DNA binding in the remodelled hearts might be due
to heterodimerization of CREB with other transcriptional
factors including ICER that thereby could antagonize CREB.
This hypothesis should be proven in future experiments.
Figure 7 ‘Second window of protection’ in healthy and remodelled hearts.
The panels show the second window of protection at 24 and 48 h after isoﬂur-
ane exposure (APC) in healthy (A) and infarct remodelled (B) hearts in the
absence (solid line) and presence (dashed line) of celecoxib (0.1 mM).
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COX-2 inhibitors increase the number of cardiovascular
complications speciﬁcally in patients with preexisting
heart disease.43 A recent pig study impressively showed
that peri-infarct inhibition of COX-2 by celecoxib decreased
myocardial function and increased left ventricular remodel-
ling and mortality.44 In the current study, we also evaluated
the effects of low and higher concentrations of the clinically
used celecoxib on late isoﬂurane protection. The IC50 of cel-
ecoxib for COX-2 (0.04 mM) is 375-times lower than for
cyclooxygenase-1,45 but celecoxib has additional unspeciﬁc
inhibitory effects on other key enzymes.21 A single oral
administration of 200 mg celecoxib results in a plasma con-
centration of 700–1100 mg/L, whereby only a small
amount (3%) of the drug is unbound and biologically
active.45 Hence, the effective tissue concentration under
clinical conditions is close to 0.1 mM, as used in our study
in the protein-free buffer perfusing the isolated hearts.
Higher concentrations of unbound drug in the range of
1 mM are unusual, but were reported in patients with
CYP2C9 deﬁciency due to genetic polymorphisms.45 Our
results clearly show that even low concentrations of cele-
coxib sufﬁce to abolish delayed protection by isoﬂurane.
Increased expression of ICER was previously reported to
downregulate prosurvival Bcl-2,41,46 and thus might well
be responsible for the higher susceptibility of infarct
hearts to celecoxib. From a translational point of view, our
data suggest that the use of selective COX-2 inhibitors
should be minimized in at-risk patients with signiﬁcant ven-
tricular remodelling. Finally, our results imply that diseased
myocardium requires more frequent intermittent precondi-
tioning stimuli to maintain the protected state.
Although previous studies showed the signiﬁcance of CREB
in establishing delayed preconditioning,47 our experiments
cannot exclude that other factors contributed to the
shorter duration of COX-2 upregulation. Our study focused
on COX-2 in healthy and diseased rat hearts, and did not
investigate molecular cross-talk between iNOS and COX-2
or other kinases such as protein kinase B. Since ischaemic
postconditioning was recently reported to enhance
delayed preconditioning by further up-regulation of
COX-2,48 future studies should test whether ischaemic and
pharmacologic postconditioning could fully restore delayed
protection by preconditioning in post-infarct hearts. Some
previous studies showed divergent mechanisms during the
early, late and ﬁnal stage of delayed preconditioning.49
Although our ﬁndings suggest that delayed isoﬂurane pre-
conditioning is mediated via the same mechanisms through-
out its duration, we cannot exclude that other or additional
mechanisms may be involved in the ﬁnal stage (at 72 h) of
late isoﬂurane protection. Finally, timing of protection is
often species-dependent and may be different in humans.
In summary, our study shows that post-infarct remodelling
in rat hearts hinders sustained COX-2 expression and activity
after isoﬂurane preconditioning and thus narrows the second
window of protection. Isoﬂurane induces nuclear transloca-
tion of HIF1a in both healthy and remodelled hearts, but
fails to mobilize the transcription factor CREB in diseased
ICER-overexpressing hearts. The study further demonstrates
that innate protection of remodelled myocardium is excep-
tionally vulnerable to COX-2 inhibition. Hence, protection
by delayed isoﬂurane preconditioning varies with the
disease state of the heart and concomitant medication.
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